Hexarelin Review 2026: The Most Potent GHRP, With the Most Baggage and the Most Interesting Heart Data

Hexarelin produces the strongest growth hormone pulse in the GHRP class. Stronger than GHRP-6, stronger than GHRP-2, stronger than Ipamorelin on a microgram-for-microgram basis. That's the headline.

Here's everything underneath it: it raises cortisol, prolactin, and ACTH alongside GH in ways that Ipamorelin was specifically engineered to avoid. It desensitizes the pituitary faster than any other GHRP, making continuous protocols essentially counterproductive within weeks. And it has a GH-independent cardioprotective mechanism via the CD36 receptor in cardiac tissue that no other GHRP shares.

The most potent. The least selective. The fastest to stop working. And the only one with direct heart data. That combination of extremes is the entire Hexarelin story.

Key Takeaways

• Highest GH pulse amplitude in the GHRP class; ED50 of 0.48 mcg/kg IV, lower than GHRP-6 or GHRP-2
• Significant cortisol (+40 to 80%), prolactin (+80%), and ACTH co-elevation at standard GH-releasing doses, unlike Ipamorelin which doesn't raise them even at 200-fold the GH ED50
• Fastest and most pronounced pituitary desensitization in the GHRP class; measurable GH response decline within weeks of continuous use
• GH-independent cardioprotective effects via the CD36 receptor in cardiac tissue; proven in CD36-null mouse studies and hypophysectomized animals
• Human pilot cardiovascular data exists in ischemic cardiomyopathy patients
• Developed at Europeptides (France) and studied extensively by Ezio Ghigo's group in Italy; Western academic research provenance
• WADA prohibited. Research chemical. No FDA approval

Hexarelin, In Simple Terms

• What a GHRP is: Growth hormone releasing peptides are synthetic molecules that mimic ghrelin (the hunger hormone) and tell your pituitary gland to release a pulse of growth hormone. Different GHRPs do this with different potency and different side effects.
• Where Hexarelin sits: It's the most powerful GHRP for raw GH output. But "most powerful" comes with "least selective." It triggers cortisol (a stress hormone that breaks down muscle), prolactin (which interferes with sexual function at high levels), and ACTH alongside the GH pulse. Ipamorelin produces a cleaner GH signal without those extras.
• What CD36 cardiac effects mean: Hexarelin binds to a receptor called CD36 in your heart muscle, producing cardioprotective signaling that has nothing to do with growth hormone. This was proven by testing it in animals with their pituitary glands removed (so GH couldn't be a factor). The heart protection still happened.
• The desensitization problem: Your pituitary gland responds to Hexarelin by releasing GH, but if you keep stimulating it daily without breaks, the receptors downregulate (turn off) and the GH response drops measurably within weeks. This is worse with Hexarelin than with any other GHRP because of its potency and stability.
• Who this is for: Not a general-purpose GH secretagogue. Ipamorelin is cleaner for most applications. Hexarelin is a specific tool for short, intense GH cycles, or a research compound of interest for its cardiac mechanism. Not a superior general option.

Table of Contents

1. What is Hexarelin?
2. The GHRP evolution
3. How it works
4. The cardiac application: CD36
5. Desensitization
6. The cortisol and prolactin problem
7. Sleep architecture warning
8. Hexarelin vs Ipamorelin vs GHRP-6
9. What does the evidence show?
10. IGF-1 implications
11. Side effects
12. Dosing
13. What happens when you stop?
14. Legal status
15. Unanswered questions
16. Final take
17. FAQ

What is Hexarelin?

Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide (six amino acids) growth hormone releasing peptide developed at Europeptides in France and studied extensively by Ezio Ghigo's endocrinology group at the University of Turin in Italy. It acts as a ghrelin mimetic, binding the growth hormone secretagogue receptor (GHSR-1a) at the pituitary and hypothalamic level.

The structure includes D-amino acids (specifically D-2-methyltryptophan) that were engineered to resist enzymatic cleavage, making Hexarelin far more metabolically stable than native ghrelin and giving it an IV half-life of approximately 70 minutes. That stability matters; native ghrelin has a half-life of minutes, while Hexarelin persists in the blood much longer, relentlessly stimulating the GHSR-1a receptor. This engineered persistence is both the source of its potency and, as we'll see, the root cause of its desensitization problem.

The GHRP Evolution and Where Hexarelin Fits

GHRPs evolved along two paths simultaneously: toward higher potency and toward better selectivity. Hexarelin represents the high-potency endpoint. Ipamorelin represents the high-selectivity endpoint. GHRP-6 sits in the middle.

The class started with GHRP-6, which was potent but raised cortisol, prolactin, and hunger. Researchers then produced Hexarelin for maximum GH output, and separately produced Ipamorelin for maximum selectivity (GH without cortisol, prolactin, or significant hunger). The field moved toward Ipamorelin for clinical applications because selectivity matters more than raw potency when you're dosing someone chronically. Hexarelin remained a research tool and a niche choice for short, intense protocols.

How Hexarelin Works

GHSR-1a Pathway (GH Release)

Hexarelin binds the ghrelin receptor (GHSR-1a) at both pituitary and hypothalamic levels, stimulating GH secretion with the highest pulse amplitude in the GHRP class. It also partially suppresses somatostatin (the hormone that inhibits GH release), creating a wider GH pulse window. The GH response is age-dependent, with young adults showing the strongest response and elderly subjects showing reduced but still significant GH release.

Cortisol, Prolactin, and ACTH Co-Stimulation

This is not a minor footnote. Hexarelin produces ACTH-releasing activity comparable to CRH (corticotropin-releasing hormone, the body's primary cortisol trigger) and stimulates prolactin through mechanisms that appear at least partially independent of both CRH and vasopressin pathways. At standard GH-releasing doses, cortisol rises 40 to 80%, prolactin rises approximately 80%. These are significant hormonal perturbations that directly counteract the anabolic goals most users have.

CD36 Receptor Pathway (Heart, GH-Independent)

This gets its own section below because it's the most scientifically significant aspect of Hexarelin.

Peripheral Ghrelin Receptor Effects

Hexarelin also activates peripheral GHSR-1a expression in the GI tract, producing gastric motility effects and moderate appetite stimulation (less than GHRP-6 but more than Ipamorelin).

The Cardiac Application: GH-Independent Cardioprotection

This is what separates Hexarelin from every other GHRP and makes it scientifically distinctive beyond raw GH output.

CD36 (fatty acid translocase) is an 88 kDa glycoprotein expressed on cardiomyocytes (heart muscle cells) and microvascular endothelial cells. Hexarelin binds CD36 directly, producing cardioprotective signaling through a pathway entirely separate from the GH-IGF-1 axis.

The proof that this is GH-independent: cardioprotective effects of Hexarelin were absent in CD36-null mice (confirming receptor dependence) and present in hypophysectomized (pituitary-removed) animals where GH secretion is impossible. The heart protection happens whether or not GH is released.

What the evidence shows: Hexarelin protects against ischemia-reperfusion injury (the damage that occurs when blood flow returns to oxygen-deprived heart tissue), improves left ventricular function in heart failure models, suppresses atherosclerotic plaque formation, and preserves cardiac function after experimentally induced heart attacks in animal models.

Human data exists: pilot studies in patients with ischemic cardiomyopathy showed cardiovascular signals. The data is limited and didn't lead to pharmaceutical development, but it puts Hexarelin in a very select group of compounds with any human cardiovascular data at all.

Desensitization: The Central Practical Limitation

This isn't a minor caveat or a theoretical concern. It's the primary reason Hexarelin isn't used for chronic GH augmentation.

Rapid desensitization of the GHSR-1a occurs with continuous Hexarelin exposure. In vitro studies demonstrated acute desensitization of intracellular calcium signaling in GHSR-transfected cells. In vivo, the GH response measurably declines with continuous dosing: effects typically plateau or diminish by weeks 4 to 6, with pronounced desensitization by week 4 in most protocols.

Why it happens so fast with Hexarelin specifically: Native ghrelin has a half-life of minutes and clears quickly, giving receptors time to recover between natural pulses. Hexarelin is engineered with D-amino acids to resist enzymatic cleavage. It survives in the blood far longer, bombarding the GHSR-1a receptors relentlessly. The pituitary responds to this unyielding stimulation by downregulating the receptors to protect itself. The very engineering that makes Hexarelin potent is what makes it self-defeating on continuous protocols.

Recovery: Pituitary sensitivity recovers over weeks of cessation, though the exact timeline depends on duration of use and dosing intensity. This is why cycle-based protocols (4 to 8 weeks on, equal or longer off-periods) aren't just preferred; they're essentially required.

The Cortisol and Prolactin Problem

Cortisol is catabolic (breaks down tissue). If you're using a GH secretagogue for body composition improvement, chronically elevated cortisol from repeated Hexarelin dosing works directly against that goal, promoting fat storage, breaking down muscle protein, and disrupting sleep. The cortisol elevation from Hexarelin is significant and well-documented, comparable in magnitude to CRH stimulation.

Prolactin elevation has implications for sexual function (reduced libido, erectile dysfunction), mood, and with extended use, dopamine system interference. The approximately 80% prolactin rise with Hexarelin is not subtle.

For comparison: Ipamorelin doesn't significantly elevate cortisol, ACTH, or prolactin even at doses 200-fold above its GH ED50. That's the selectivity difference in stark terms.

Hexarelin: Sleep Architecture Warning

Standard GHRP protocol is evening dosing because GH is naturally released during deep sleep. Ipamorelin supports this logic; it promotes slow wave sleep. Hexarelin does the opposite. Because it triggers a massive co-release of cortisol and ACTH, evening dosing frequently destroys sleep architecture. Users report waking up sweating, wired, and exhausted.

Hexarelin requires a completely different timing protocol than Ipamorelin. Morning or early afternoon dosing avoids the cortisol-mediated sleep disruption. This isn't widely communicated and catches new users off guard.

Hexarelin vs Ipamorelin vs GHRP-6

The field moved toward Ipamorelin for general use because most applications benefit more from a clean, sustainable GH signal than from a massive but self-limiting spike accompanied by cortisol and prolactin.

What Does the Hexarelin Evidence Show?

GH Pulse Amplitude

The dose-response study in healthy adult males showed GH peaks of approximately 55 mcg/L at standard doses, substantially exceeding GHRP-6 and GHRP-2 at equivalent doses. The GH response plateaus at around 1.0 mcg/kg IV; higher doses don't increase GH further but do continue to increase cortisol and prolactin, making lower doses more selective for GH.

Body Composition

GH-mediated fat loss and lean mass effects are expected downstream of the GH-IGF-1 axis. The cortisol co-elevation complicates interpretation because cortisol promotes fat storage and muscle breakdown, partially counteracting the anabolic signal.

Cardiovascular Protection

The CD36-mediated cardioprotection is documented across ischemia-reperfusion models, heart failure models, and atherosclerosis models. Human pilot data in ischemic cardiomyopathy patients exists.

IGF-1 Implications

Same honest treatment as all GH secretagogues: sustained GH elevation raises IGF-1 levels, which is associated with cancer risk in observational data and theoretical acromegaly (excessive growth) concerns at supraphysiological levels. The cortisol co-elevation adds a second endocrine concern on top of IGF-1, making the long-term hormonal burden more complex than with Ipamorelin. Anyone with cancer history, active malignancy, or family history of hormone-sensitive cancers should be especially cautious.

Hexarelin Side Effects

The "Hexarelin flush": Almost immediately after subcutaneous injection, many users experience rapid, intense heartbeat, facial flushing, and sweating. This results from CD36 cardiovascular receptor activation combined with the sudden spike in prolactin and ACTH. It terrifies first-time users who aren't warned about it. It's transient but intense.

Cortisol elevation: Catabolic burden, potential sleep disruption with evening dosing, adrenal stress with chronic use.

Prolactin elevation: Sexual function interference, mood effects, dopamine system disruption with extended use.

Water retention: GH-mediated sodium retention. Same mechanism as all GH secretagogues.

Hunger stimulation: Present but less than GHRP-6.

Facial flushing and tingling: Standard GHRP class effects.

Desensitization: Functionally the most important "side effect" because it limits the compound's own utility.

Hexarelin Dosing

What Happens When You Stop Hexarelin?

GH returns to baseline. Cortisol and prolactin normalize. IGF-1 normalizes over days to weeks. Pituitary sensitivity recovers, with timeline depending on duration and intensity of use. No dependency or withdrawal.

Legal Status of Hexarelin

Research chemical everywhere. No FDA approval. No active pharmaceutical development program (the cardiac application is the most likely candidate for revival but no sponsor is currently pursuing it). WADA prohibited in competitive sport; GHRPs are banned as a class. Detection methods exist and are applied.

Unanswered Questions

1. Will the CD36 cardiac application ever be developed independently of GH stimulation? A modified Hexarelin analog that preserves the cardiac effect while eliminating the GH/cortisol/prolactin/desensitization package would be genuinely valuable.
2. Does the cortisol burden actually undermine body composition goals at typical doses over a full cycle? The catabolic vs anabolic balance hasn't been quantified in a controlled setting.
3. What does pituitary sensitivity recovery actually require? The off-cycle duration needed after 4, 8, or 12 weeks of use hasn't been systematically characterized.
4. Can the cardiac mechanism be separated from GHSR-1a activation through dose or formulation? CD36 binding may have a different dose-response than GHSR-1a, which could allow cardiac-selective dosing.

Final Take

Hexarelin has the highest GH output in the GHRP class, the worst desensitization, the worst cortisol/prolactin profile, and the most interesting cardiac application. The CD36-mediated cardioprotection is the most scientifically distinctive thing about it, and the angle most likely to have a future development pathway if anyone picks it up.

For general GH secretagogue use, Ipamorelin's selectivity makes it a more practical choice for the vast majority of applications. Hexarelin's unique profile is a specific tool for short, intense cycles where maximum GH pulse amplitude matters more than sustainability, or a research compound of genuine scientific interest for its cardiac mechanism. It's not a superior general option. It's a specialized one with real trade-offs that need honest acknowledgment.

FAQ

Is Hexarelin the strongest GHRP?

Yes. Highest GH pulse amplitude in the class at the lowest effective dose.

Why not just use Hexarelin instead of Ipamorelin?

Because it raises cortisol and prolactin significantly, desensitizes the pituitary within weeks, and can disrupt sleep. Ipamorelin doesn't do any of those things. More GH isn't better if it comes with hormones that work against your goals.

What's the CD36 cardiac effect?

Hexarelin binds CD36 in heart tissue and produces cardioprotective signaling completely independent of growth hormone. Proven in animals without pituitaries.

How long can I run it?

4 to 8 weeks maximum before desensitization makes it counterproductive. Equal or longer off-periods for pituitary recovery.

Can I take it before bed?

Not recommended. Cortisol and ACTH co-release disrupts sleep architecture. Morning or early afternoon dosing is better.

What's the flush after injection?

Rapid heartbeat, facial flushing, sweating. CD36 activation plus sudden prolactin/ACTH spike. Transient but alarming if you're not warned. Expected, not dangerous.

Is it FDA-approved?

No. Research chemical. WADA prohibited.